Cytodyn Inc (CYDY)

[kgromax]

But your Cytodyn mortality number is not compatible with the 65 US ICUs statistics, West Coast to East coast, North to South...if I use your number, the placebo arm would end up having a higher mortality for Severe+Critical patients than what all these ICUs have with Critical+Overcritical patients...and 50+ independant global studies confirm the US ICUs numbers... they are all consistent together, taken from different countries, while your number is not.

Regarding the EIND papers, you realize they suffer from important methodological biases? Like some patients handpicked (or, conversely, non included) from the papers. Such biases make the number non representative. Also with so few patients the numbers you quote are not statistically significant. With 2000+ patients (and much more if you include the other 50+ global studies), the ICUs study figures are MUCH more precise and significant. Taken together, huge biases + small pop., the EIND papers are not very useful. This is phase III, FDA is looking for hard statistics, not a couple EIND anymore.